Be among trailblazing marketing pros at Brandweek this September 23–26 in Phoenix, Arizona. Experience incredible networking, insightful sessions and a boost of inspiration at ADWEEK’s ultimate brand event. Register by May 13 to save 35%.
The Food and Drug Administration’s position on acetaminophen, the active ingredient in Tylenol, is giving parent company Johnson & Johnson a branding headache, according to researcher YouGov.
The firm, whose BrandIndex polls 5,000 U.S. adults daily on brand perception, found Tylenol’s negative buzz grew in a very short amount of time.
On June 25, the brand’s buzz score-which is rated on a scale of 100 to -100 and calculated by subtracting negative feedback from positive-was 38.9
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in